Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2032-2042
Published online before print August 25, 2005, doi: 10.1161/01.ATV.0000183728.14712.d8
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/10/2032    most recent
01.ATV.0000183728.14712.d8v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lafontan, M.
Right arrow Articles by Berlan, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lafontan, M.
Right arrow Articles by Berlan, M.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2032.)
© 2005 American Heart Association, Inc.


Brief Reviews

An Unsuspected Metabolic Role for Atrial Natriuretic Peptides

The Control of Lipolysis, Lipid Mobilization, and Systemic Nonesterified Fatty Acids Levels in Humans

Max Lafontan; Cédric Moro; Coralie Sengenes; Jean Galitzky; François Crampes; Michel Berlan

From the IFR31-Institut Louis Bugnard; Hôpital Rangueil, Institut National de la Santé et de la Recherche Médicale (Inserm), Inserm U586; the Obesity Research Unit; BP 84 225; 31432 Toulouse cedex 4; and the Université Paul Sabatier, 31052 Toulouse cedex 4, France.

Correspondence to Doctor Max Lafontan, IFR-31, Institut Louis Bugnard, Obesity Research Unit, Inserm-UPS U 586, BP 84225, 31432 Toulouse cedex 4, France. E-mail Max.Lafontan{at}toulouse.inserm.fr

In normal and obese humans, lipid mobilization and systemic nonesterified fatty acid levels are thought to be acutely controlled by catecholamines (ie, epinephrine and norepinephrine) and insulin. Natriuretic peptides (NPs) are known to play a key role in the regulation of salt and water balance and blood pressure homeostasis. They are involved in the pathophysiology of hypertension and heart failure. NPs have recently been found to exert potent lipolytic effects (ie, activating the breakdown of stored triacylglycerols) in isolated human fat cells and to promote lipid mobilization in vivo. Atrial natriuretic peptide increases the intracellular 3', 5'-cyclic guanosine monophosphate (cGMP) concentration which activates cGMP-dependent protein kinase leading to perilipin and hormone-sensitive lipase phosphorylation and lipolysis. NPs promote lipid mobilization when administered intravenously. NPs are also responsible for the residual lipid-mobilizing action observed under oral ß-blockade in subjects performing physical exercise. NPs are therefore novel factors which may open promising research pathways to explain the control of lipid mobilization in physiological and pathological conditions. The metabolic impact of altered production and circulation of NPs remains to be established. The potential influence of NPs on the development of lipid disorders, obesity-related cardiovascular events, and cardiac cachexia will be discussed in this review.

Natriuretic peptides (NPs) are novel factors which may open promising research pathways to explain the control of lipid mobilization in physiological and pathological conditions. The metabolic impact of altered production and circulation of NPs remains to be established. The potential influence of NPs on the development of lipid disorders, obesity-related cardiovascular events, and cardiac cachexia will be discussed in this review.


Key Words: adipose tissue • adipocytes • lipolysis • natriuretic peptides • obesity • lipid metabolism • lipid mobilization • insulin




This article has been cited by other articles:


Home page
Eur Heart JHome page
C. Christoffersen, I. Hunter, A. L. Jensen, and J. P. Goetze
Diabetes and the endocrine heart
Eur. Heart J., October 2, 2007; 28(20): 2427 - 2429.
[Full Text] [PDF]


Home page
CirculationHome page
T. J. Wang, M. G. Larson, M. J. Keyes, D. Levy, E. J. Benjamin, and R. S. Vasan
Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals
Circulation, March 20, 2007; 115(11): 1345 - 1353.
[Abstract] [Full Text] [PDF]